期刊文献+

An updated overview on the development of new photosensitizers for anticancer photodynamic therapy 被引量:21

原文传递
导出
摘要 Photodynamic therapy(PDT), based on the photoactivation of photosensitizers(PSs), has become a well-studied therapy for cancer. Photofrin~?, belonging to the first generation of PS, is still widely used for the treatment of different kinds of cancers; however, it has several drawbacks that significantly limit its general clinical use. Consequently, there has been extensive research on the design of PS molecules with optimized pharmaceutical properties, with aiming of overcoming the disadvantages of traditional PS, such as poor chemical purity, long half-life, excessive accumulation into the skin, and low attenuation coefficients. The rational design of novel PS with desirable properties has attracted considerable research in the pharmaceutical field. This review presents an overview on the classical photosensitizers and the most significant recent advances in the development of PS with regard to their potential application in oncology. Photodynamic therapy(PDT), based on the photoactivation of photosensitizers(PSs), has become a well-studied therapy for cancer. Photofrin~?, belonging to the first generation of PS, is still widely used for the treatment of different kinds of cancers; however, it has several drawbacks that significantly limit its general clinical use. Consequently, there has been extensive research on the design of PS molecules with optimized pharmaceutical properties, with aiming of overcoming the disadvantages of traditional PS, such as poor chemical purity, long half-life, excessive accumulation into the skin, and low attenuation coefficients. The rational design of novel PS with desirable properties has attracted considerable research in the pharmaceutical field. This review presents an overview on the classical photosensitizers and the most significant recent advances in the development of PS with regard to their potential application in oncology.
出处 《Acta Pharmaceutica Sinica B》 SCIE CSCD 2018年第2期137-146,共10页 药学学报(英文版)
基金 financially supported by the National Natural Science Foundation of China(No.21672082) Shandong Key Development Project(No.2016GSF201209) Young Taishan Scholars Program(No.tsqn20161037) Shandong Talents Team Cultivation Plan of University Preponderant Discipline(No.10027) Shandong Natural Science Foundation for Distinguished Young Scholars(JQ201721) the Brazilian Government Agencies FAP/DF(0193.001020/2015)and CNPq(447.628/2014-3)
  • 相关文献

同被引文献64

引证文献21

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部